In our study, tumor grade 3, estrogen receptor negativity, progesterone receptor negativity, HER2 strong positivity (score 3+), and the use of neoadjuvant trastuzumab were associated with higher pathological complete response rates. The gene discussed is ESR1; the disease is neoplasm.